Synthetic nanoparticles functionalized with cell membrane-mimicking, bone-targeting, and ROS-controlled release agents for osteoporosis treatment.

Zhang W, Zhang Y, Hao Z, Yao P, Bai J, Chen H, Wu X, Zhong Y, Xue D

Journal of controlled release : official journal of the Controlled Release Society18 Dec 2024Cited by 23 (Europe PMC)

PMID39694070DOI10.1016/j.jconrel.2024.12.017PepBankPUB-39694070

Publisher page PubMedAsk about this study

Summary

The text of this summary is not shown here, because the article license does not allow reuse. Read it at the source (opens in a new tab)

Text rights: Publisher copyright. Results still quote short attributed sentences.

Results from this study6

No result from this study comes from a test of the peptide.

Studies that did not test the peptide alone6

In this study, Elamipretide (SS-31) was a lab tool or a carrier, part of a mix, or the subject of a lab method. These results are not evidence about taking Elamipretide (SS-31).

01AnimalNot a test of Elamipretide (SS-31) aloneAnimal study (in vivo)Efficacy outcome
After intravenous injection, the nanoparticle ALN@BMSCM@PLGA-TK-PEG-SS31 downregulated reactive oxygen species generation in bone.
In plain wordsAfter injection, a nanoparticle carrying alendronate, stem cell membrane and SS31 lowered harmful oxygen molecules in bone.
Peptide
Elamipretide (SS-31)
Outcome
DecreaseBone ROS generation after intravenous injection
Study
n: not reported in source
Outcome group
Oxidative stress · Musculoskeletal
Source sentences
Summary
efficiently downregulated bone reactive oxygen species (ROS) generation.
1 context sentence(design, population, supporting numbers)
Summary · context
We synthesized a novel nanoparticle (NP), ALN@BMSCM@PLGA-TK-PEG-SS31.
In this study, Elamipretide (SS-31) was a lab tool or a carrier, part of a mix, or the subject of a lab method. This result is not evidence about taking Elamipretide (SS-31).
Report a problemFND-3969407003
02AnimalNot a test of Elamipretide (SS-31) aloneAnimal study (in vivo)Efficacy outcome
In mice with ovariectomy-induced osteoporosis, the nanoparticle ALN@BMSCM@PLGA-TK-PEG-SS31 significantly ameliorated oxidative stress.
In plain wordsIn mice, a nanoparticle carrying alendronate, stem cell membrane and SS31 reduced oxidative stress in a model of osteoporosis.
Peptide
Elamipretide (SS-31)
Outcome
DecreaseOxidative stress in ovariectomy-induced osteoporosis
Study
mousen: not reported in source
Ovariectomy-induced osteoporosis
Outcome group
Oxidative stress · Musculoskeletal
Source sentences
Summary
In a mouse model of ovariectomy-induced osteoporosis, ALN@BMSCM@PLGA-TK-PEG-SS31 significantly ameliorated oxidative stress
1 context sentence(design, population, supporting numbers)
Summary · context
We synthesized a novel nanoparticle (NP), ALN@BMSCM@PLGA-TK-PEG-SS31.
In this study, Elamipretide (SS-31) was a lab tool or a carrier, part of a mix, or the subject of a lab method. This result is not evidence about taking Elamipretide (SS-31).
Report a problemFND-3969407004
03AnimalNot a test of Elamipretide (SS-31) aloneAnimal study (in vivo)Efficacy outcome
In mice with ovariectomy-induced osteoporosis, the nanoparticle ALN@BMSCM@PLGA-TK-PEG-SS31 increased bone mass.
In plain wordsIn mice, a nanoparticle carrying alendronate, stem cell membrane and SS31 increased bone mass in a model of osteoporosis.
Peptide
Elamipretide (SS-31)
Outcome
IncreaseBone mass in ovariectomy-induced osteoporosis
Study
mousen: not reported in source
Ovariectomy-induced osteoporosis
Outcome group
Bone and joint · Musculoskeletal
Source sentences
Summary
In a mouse model of ovariectomy-induced osteoporosis, ALN@BMSCM@PLGA-TK-PEG-SS31 significantly ameliorated oxidative stress and increased bone mass
1 context sentence(design, population, supporting numbers)
Summary · context
We synthesized a novel nanoparticle (NP), ALN@BMSCM@PLGA-TK-PEG-SS31.
In this study, Elamipretide (SS-31) was a lab tool or a carrier, part of a mix, or the subject of a lab method. This result is not evidence about taking Elamipretide (SS-31).
Report a problemFND-3969407005
04AnimalNot a test of Elamipretide (SS-31) aloneAnimal study (in vivo)Safety outcome
In mice with ovariectomy-induced osteoporosis, the nanoparticle ALN@BMSCM@PLGA-TK-PEG-SS31 caused no notable systemic side effects.
In plain wordsIn mice, a nanoparticle carrying alendronate, stem cell membrane and SS31 caused no notable side effects in the body.
Peptide
Elamipretide (SS-31)
Outcome
No significant changeSystemic side effects
Study
mousen: not reported in source
Ovariectomy-induced osteoporosis
Outcome group
Adverse events · Musculoskeletal
Source sentences
Summary
In a mouse model of ovariectomy-induced osteoporosis, ALN@BMSCM@PLGA-TK-PEG-SS31 significantly ameliorated oxidative stress and increased bone mass with no notable systemic side effects
1 context sentence(design, population, supporting numbers)
Summary · context
We synthesized a novel nanoparticle (NP), ALN@BMSCM@PLGA-TK-PEG-SS31.
In this study, Elamipretide (SS-31) was a lab tool or a carrier, part of a mix, or the subject of a lab method. This result is not evidence about taking Elamipretide (SS-31).
Report a problemFND-3969407006
05LabNot a test of Elamipretide (SS-31) aloneIn vitro (cells)Efficacy outcome
In vitro, the nanoparticle ALN@BMSCM@PLGA-TK-PEG-SS31 significantly inhibited RANKL-induced osteoclastogenesis in the presence of H2O2.
In plain wordsIn lab tests, a nanoparticle carrying alendronate, stem cell membrane and SS31 blocked formation of bone-resorbing cells.
Peptide
Elamipretide (SS-31)
Outcome
DecreaseRANKL-induced osteoclastogenesis
Study
n: not reported in source
RANKL-induced osteoclast culture with H2O2
Outcome group
Bone and joint · Musculoskeletal
Source sentences
Summary
significantly inhibiting RANKL-induced osteoclastogenesis in the presence of H₂O₂
1 context sentence(design, population, supporting numbers)
Summary · context
We synthesized a novel nanoparticle (NP), ALN@BMSCM@PLGA-TK-PEG-SS31.
In this study, Elamipretide (SS-31) was a lab tool or a carrier, part of a mix, or the subject of a lab method. This result is not evidence about taking Elamipretide (SS-31).
Report a problemFND-3969407001
06LabNot a test of Elamipretide (SS-31) aloneIn vitro (cells)Efficacy outcome
In vitro, the nanoparticle ALN@BMSCM@PLGA-TK-PEG-SS31 promoted osteogenic differentiation in BMSCs.
In plain wordsIn lab tests, a nanoparticle carrying alendronate, stem cell membrane and SS31 promoted bone-forming differentiation of stem cells.
Peptide
Elamipretide (SS-31)
Outcome
IncreaseOsteogenic differentiation of BMSCs
Study
n: not reported in source
Bone marrow mesenchymal stem cells (BMSCs)
Outcome group
Bone and joint · Musculoskeletal
Source sentences
Summary
promoting osteogenic differentiation in BMSCs.
1 context sentence(design, population, supporting numbers)
Summary · context
We synthesized a novel nanoparticle (NP), ALN@BMSCM@PLGA-TK-PEG-SS31.
In this study, Elamipretide (SS-31) was a lab tool or a carrier, part of a mix, or the subject of a lab method. This result is not evidence about taking Elamipretide (SS-31).
Report a problemFND-3969407002

AI wrote and checked these results. AI can make mistakes, so check important results against the source.

Version history

PepBank keeps every version of the data on this study. Status changes from Retraction Watch, Europe PMC and Crossref are listed with their source.

Version 2Current
10 Oct 2026, 08:19 UTC
Study results updated
Version 1
9 Oct 2026, 02:47 UTC
First added · source update from Europe PMC

Subjects

Terms as the source lists them.

PepBank is a research reference. Talk to a doctor before you use any peptide.